The present disclosure relates to a bio-material composition comprising a dry potassium phosphate based mixture omprising: MgO, monobasic potassium phosphate, monobasic sodium phosphate, proteoglycans, calcium sodium phosphosilicate, and an antibiotic, wherein a weight percent ratio of monobasic potassium phosphate to MgO is between about 3:1 and 1:1, wherein the dry otassium phosphate based mixture is configured to be mixed with the aqueous solution to thereby form a reabsorbable bio-material slurry, wherein the proteoglycans are between about 1-10 weight percent of the dry composition, and wherein the proteoglycans act as active regulators of collagen fibrillogenesis to thereby structure tissue of a patient by organizing a bone extracellular matrix.

A multi-component system alloy includes titanium, zirconium, niobium, molybdenum, and tantalum, and further the multi-component system alloy includes at least one selected from the group consisting of hafnium, tungsten, vanadium, and chromium, wherein the alloy satisfies Mo equivalent ≧ 13.5, and the alloy is a single-phase solid solution, a two-phase solid solution, or an alloy in which a main phase is a solid solution phase.

The invention relates to biodegradable, magnesium alloys, compositions and composites, methods for their preparation and applications for their use as implantable medical devices in load-bearing conditions. The magnesium alloys are composed of alloying elements selected from yttrium, calcium, zirconium, zinc, and strontium, with the remainder being magnesium and impurities due to production, and are prepared by melting together the elements and casting the resulting melted mixture. In certain embodiments, the methods of preparation include solution treatment and hot extrusion.

Hard-tissue implants are provided that include a bulk implant, a face, pillars, slots, and at least one support member. The pillars are for contacting a hard tissue. The slots are to be occupied by the hard tissue. The at least one support member is for contacting the hard tissue. The hard-tissue implant has a Young's modulus of elasticity of at least 3 GPa, and has a ratio of the sum of (i) the volumes of the slots to (ii) the sum of the volumes of the pillars and the volumes of the slots of 0.40:1 to 0.90:1. Methods of making and using hard-tissue implants are also provided.

A medical implant includes a first implant body and a pre-coating covering at least a portion of an outer surface of the first implant body. The pre-coating has a negative Poisson's ratio. A method of making a medical implant includes applying a precursor material on a surface of a first implant body, the first implant body having a positive Poisson's ratio. A stimulus is applied to the precursor material, the stimulus causing the precursor material to form a coating having a negative Poisson's ratio

The present disclosure features adhesive compositions and methods of use thereof related to the medical, veterinary, and dental fields.

The present disclosure provides a bone-implantable device and methods of use. The bone-implantable device comprises a body having an exterior surface, wherein a portion of the exterior surface includes a cured osteostimulative material comprising MgO.

An implant for treating a bone defect wherein the implant comprises osteoconductive supporting bodies and an insertion aid. The insertion aid is designed for insertion of the osteoconductive supporting bodies into a bone defect and for holding together the osteoconductive supporting bodies. Also disclosed is a kit comprised of an implant for treating a bone defect.

An osteotomy implant includes a first surface extending generally in a first plane and a second surface extending generally in a second plane, oblique to the first plane. The first surface has a perimeter having a first linear edge, a first curve edge connected to the first linear edge, a second linear edge connected to the first curved edge, and a second curved edge connected to the second liner edge.

An inducer is directed to the induction of in situ regeneration in regenerative medicine. The inducer including an extracellular matrix and/or a bone morphogenetic protein, can induce the regeneration of bone and soft tissues surrounding the bone such as muscle, blood vessel and skin at the residual tissues where trauma occurs. The amount of regenerated tissue is associated with the dose of the implanted inducer.